Mymetics is the global leader in know-how and research for virosome based vaccines.
Our vaccines candidates against infectious diseases, like HIV and SARS-CoV-2 are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.
Our vaccine candidates/immunotherapies for Oncology are focused on triggering the right specific immune response, CD8+ and CD4+ T cells.
Our virosome vaccine platform is being validated through partnerships with leading pharmaceutical, biotech, and research organisations.
Mymetics Corporation (OTCQB: MYMX) is a Swiss-based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB, a venture stage market place.